FIELD: pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutics, namely to the use of benzbromarone for preparing a drug for preventing or treating keloid scars or hypertrophic scars and for making a drug for reducing the size of the scar on the skin. Use of benzbromarone for preparing a drug for preventing or treating keloid scars or hypertrophic scars. Use of benzbromarone for preparing a drug for reducing the size of the scar on the skin.
EFFECT: said group of inventions enables to obtain medicinal agents which can be successfully used to prevent or treat scars, including for reduction of their size.
6 cl, 15 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLYING OLTIPRAZ FOR PROPHYLAXIS AND TREATMENT OF LIVER FIBROSIS AND CIRRHOSIS AND OLTIPRAZ-CONTAINING PHARMACEUTICAL COMPOSITION | 2001 |
|
RU2258509C2 |
| LIPOSOMS WITH RETYNOID TO STRENGTHEN hsp47 EXPRESSION MODULATION | 2012 |
|
RU2628694C2 |
| PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING THE CASES OF PROGRESSING HEPATIC FIBROSIS AND CIRRHOSIS | 2001 |
|
RU2250768C2 |
| PEPTIDES INHIBITING GROWTH TRANSFORMING FACTOR TGF-BETA-1 | 1999 |
|
RU2232771C2 |
| USE OF CHIGLITAZAR AND RELATED COMPOUNDS | 2019 |
|
RU2769446C1 |
| AGENT FOR TREATING RENAL FIBROSIS | 2011 |
|
RU2711531C2 |
| MEANS FOR KIDNEY FIBROSIS TREATMENT | 2011 |
|
RU2635460C2 |
| USE OF VAP-1 INHIBITORS FOR FIBROTIC SICKNESS TREATMENT | 2010 |
|
RU2580626C2 |
| AGENT FOR TREATING MYELOFIBROSIS | 2009 |
|
RU2557997C2 |
| USE OF DNA SEQUENCE WHICH CODES PEPTIDE ABLE TO BIND WITH TRANSFORMING GROWTH FACTOR β1 (VERSIONS) | 2008 |
|
RU2455358C2 |
